RecruitingNot ApplicableNCT06830096

Role of KATP Channel Loss in Type 2 Diabetes

Hyperglycemia Induced Hyperexcitability: A Novel Role for KATP in the Progression of Type 2 Diabetes

Sponsor

Washington University School of Medicine

Enrollment

40 participants

Start Date

Mar 7, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity and Type 2 Diabetes

Summary

Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 diabetes. Intriguingly, evidence from cell and animal models suggest that chronically stimulated β-cells can lose KATP revealing a possible role for KATP loss in the failure of insulin secretion and poor control of blood sugar observed in type 2 diabetes. This study will therefore examine insulin responses following ingestion of a single dose of a sulfonylurea called glipizide that inhibits KATP channels in people with and without type 2 diabetes. The goal is to determine whether KATP channel activity is reduced during type 2 diabetes progression.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating the role of a specific protein channel (KATP channel) in how the body regulates insulin secretion and blood sugar in people with normal weight, obesity without diabetes, pre-diabetes (impaired fasting glucose), and Type 2 diabetes. It uses detailed metabolic testing to understand why some people with obesity develop Type 2 diabetes and others don't. **You may be eligible if...** - You are an adult who falls into one of four groups: 1. Lean with normal blood sugar 2. Obese with normal blood sugar 3. Obese with mildly elevated fasting blood sugar (pre-diabetes range: 100–125 mg/dL) 4. Type 2 diabetes managed with metformin alone - You have a BMI in the appropriate range for your group (18.5–25 for lean, 30–50 for obese groups) - You are not currently using insulin **You may NOT be eligible if...** - You are currently on insulin therapy - You are taking medications (other than metformin for the diabetes group) that affect blood sugar or insulin - You have significant kidney, liver, or cardiovascular disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.